PI3K isoform-selective inhibitors: next-generation targeted cancer therapies
Acta Pharmacologica Sinica2015Vol. 36(10), pp. 1170–1176
Citations Over TimeTop 10% of 2015 papers
Related Papers
- → Idelalisib: First Global Approval(2014)115 cited
- → The PI3K pathway: clinical inhibition in chronic lymphocytic leukemia(2016)43 cited
- → Idelalisib-related pneumonitis(2016)31 cited
- → <p>Rapid and complete response to idelalisib in a case of Richter syndrome</p>(2019)9 cited
- → Idelalisib: Practical Tools for Identifying and Managing Adverse Events in Clinical Practice(2016)2 cited